Top

News & Events

Client News

Client News

Clinigen hosts Unlicensed Medicines satellite symposium at 22nd Congress of EAHP

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or ‘the Group’), the global pharmaceuticals and services group, announces that its Idis GA division is holding a satellite symposium today on Access to Unlicensed Medicines as part of the 22nd Congress of European Association of Hospital Pharmacists (EAHP), taking place in Cannes, France.

Read more »

SkinBioTherapeutics intention to launch Initial Public Offering and list on AIM

Manchester, UK - SkinBioTherapeutics plc (“SkinBio” or the “Company”), a life science company focused on skin health, intends to seek Admission to AIM with an associated institutional and private client fundraising.

Read more »

European Group on Tumour Markers (EGTM) Updated Guidelines Recommend Agendia’s MammaPrint® Test with Highest Level 1A Clinical Evidence

Irvine, CA, USA and Amsterdam, the Netherlands - Agendia, a world leader in personalized medicine and molecular cancer diagnostics, announces that updated guidelines from the European Group on Tumour Markers (EGTM), published recently online in the European Journal of Cancer (EJC), name the MammaPrint® 70-Gene Breast Cancer Risk-of-Recurrence test as the first and currently the only multigene test of its kind deemed to have level 1A evidence for its clinical use.1

Read more »

AdAlta expands partnership with world-leading fibrosis research team at Melbourne’s The Alfred Hospital

MELBOURNE Australia: AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development today announced the continuation of its collaboration with The Alfred hospital in Melbourne, Australia, and the clinical research team led by Dr Glen Westall, an expert in lung fibrosis and Idiopathic Pulmonary Fibrosis (IPF).

Read more »

Auspherix to Present Organogold Pipeline at Superbugs & Superdrugs

Stevenage, UK – Auspherix Limited, the anti-infectives company meeting the urgent need for new antibiotics by developing a novel class of antibacterials, is pleased to announce that it has been invited to present at this year’s Superbugs & Superdrugs conference in London, 20-21 March 2017.

Read more »

Mission Therapeutics Strengthens Senior Leadership Team with the Appointment of Dr Anne Phelan as Senior Vice President, Head of Discovery Research

Cambridge, UK – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat cancer, neurodegenerative and other diseases, announced the appointment of Dr Anne Phelan as Senior Vice President, Head of Discovery Research, effective 20 March 2017.

Read more »

Cell Medica: £60 million Series C financing to advance multiple cancer programmes

London, UK – Cell Medica (or ‘the Company’), a leading cellular immunotherapy company, has closed a £60 million Series C investment round with participation from existing investors Touchstone Innovations, funds managed by Invesco Perpetual, and funds managed by Woodford Investment Management.

Read more »

Innovations invests £13.7m in £60.0m funding round in Cell Medica

Touchstone Innovations plc (AIM: IVO, ‘the Group’, ‘Innovations’) has participated in a £60.0m funding round in Cell Medica Limited (“Cell Medica” or “the Company”) committing £13.7 million to the round alongside co-investors Invesco Asset Management and Woodford Investment Management.

Read more »

Clinigen and Diurnal partner for European Managed Access programme for Infacort® and Chronocort®

Clinigen Group plc’s (AIM: CLIN, ‘Clinigen’ or the ‘Group’) Idis Managed Access (MA) division and Diurnal Group plc (AIM: DNL, ‘Diurnal’), have partnered to launch a Managed Access programme in Europe for Infacort® to treat paediatric patients with adrenal insufficiency (AI) and Chronocort® to treat patients with congenital adrenal hyperplasia (CAH).

Read more »

Patents licensed to Synthon relating to the CD47-SIRPα pathway resist challenges in the U.S. and Europe

Nijmegen, The Netherlands – On 9 February 2017, the Patent Trial and Appeal Board of the United States Patent and Trademark Office (USPTO) denied institution of Forty Seven Inc.’s petitions for inter partes review of the US 9,352,037 patent which was issued in May 2016.

Read more »

Autifony Therapeutics obtains £1.3 million in funding from Innovate UK and the Dementia Discovery Fund to explore novel approach to treatment of dementia

Stevenage, UK - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, today announced a new funding award of £895,000 from the Biomedical Catalyst for initiation of a research programme with a novel approach to the treatment of dementia. An investment of £400,000 from the Dementia Discovery Fund (“DDF”) will also be used to pursue this highly novel approach to dementia treatment.

Read more »

Clinigen Group plc: STRONG H1 PERFORMANCE WITH ADJUSTED EPS UP 31%*

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or ‘the Group’), the global pharmaceuticals and services company, today publishes its half year results for the six months ended 31 December 2016.

Read more »

Cambridge-based Astex Pharmaceuticals Celebrates as Cancer Drug Receives US Marketing Approval

Cambridge, UK – Astex Pharmaceuticals (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that its long-standing pharmaceutical collaborator, Novartis, has received US Food and Drug Administration (FDA) marketing approval for Kisqali® (ribociclib, formerly known as LEE011) plus an aromatase inhibitor as a first-line treatment in post-menopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced (metastatic) breast cancer.

Read more »

First-in-class Fycompa® (perampanel) approved in South Africa for partial-onset seizures

Clinigen Group plc - Eisai is pleased to announce that perampanel has been approved in South Africa for the adjunctive treatment of partial-onset seizures, with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.1 Perampanel is the first anti-epileptic drug to be approved in South Africa in recent years.

Read more »

German Community of Gynecological Oncology (AGO) Acknowledges MammaPrint in Breast Cancer Guidelines as Having Level 1A Clinical Evidence

Irvine, CA, USA and Amsterdam, the Netherlands - Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces that the company’s MammaPrint® 70-Gene Breast Cancer Risk-of-Recurrence test is now included with the highest medical evidence level 1A in the latest version of AGO (German Association of Gynecological Oncology) guidelines for the care of breast cancer patients in Germany.

Read more »

DNAe Appoints International Infectious Disease Experts to its Newly Formed Clinical Advisory Board

London, UK and Carlsbad, CA, USA – DNA Electronics (‘DNAe’), the inventors of semiconductor DNA sequencing technology and developers of a new, revolutionary blood-to-result test for bloodstream infections, announces the formation of its clinical advisory board (CAB). The CAB, with founding members Professor Paul Dark, Professor Angela Caliendo, Professor Stephan Harbarth and Professor Romney Humphries, brings together US and European experts to provide strategic guidance for the clinical development of DNAe’s diagnostic platform, LiDia™, and its accompanying range of tests for different clinical applications.

Read more »

‘Abzena inside’ product for neurodegenerative conditions moves into Phase II trial

Cambridge, UK - Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, notes that one of the ‘Abzena inside’ Composite Human Antibody™ products previously disclosed as being in Phase I trials is moving forwards into a Phase II clinical trial.

Read more »

Dr Igor Matushansky Appointed Global Head, Research and Development of Hookipa Biotech

Vienna, Austria - Hookipa Biotech AG, a company pioneering a new class of immunotherapies for oncology and infectious diseases, today announces the appointment of Igor Matushansky, M.D., Ph.D. as Global Head, Research and Development. The appointment is effective from today.

Read more »

Staten Biotechnology exercises option to develop therapeutic SIMPLE AntibodyTM for dyslipidemia from argenx N.V.

Nijmegen, The Netherlands – Staten Biotechnology, a company focused on the treatment of dyslipidemia and reduction of cardiovascular mortality today announced that it has exercised an exclusive option to license ARGX-116 (STT-5058), an anti-ApoC3 SIMPLE Antibody from argenx N.V.

Read more »

Synthon enters worldwide exclusive license and collaboration with Sanquin for immuno-oncology therapeutic leads modulating the CD47-SIRPα pathway

Nijmegen and Amsterdam, The Netherlands - Synthon Biopharmaceuticals BV, an international biopharmaceutical company that is focused on developing new molecular entities for treating cancer and autoimmune diseases, today announced that it has entered a license and collaboration agreement for the development of novel immuno-oncology antibodies with Sanquin Blood Supply Foundation (‘Sanquin’), Amsterdam.

Read more »

Abzena plc: Medical Research Council grant awarded to collaboration group developing novel autoimmune therapy

Cambridge and London, UK - Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products and UCL (University College London), one of the world’s leading multidisciplinary universities, supported by UCL Business, the technology commercialisation company of UCL, announce that a research group from UCL’s Centre for Rheumatology has been awarded a £3.5m grant from the Medical Research Council (MRC) to progress the development of a novel treatment for anti-phospholipid syndrome (APS) which uses Abzena’s proprietary conjugation technology.

Read more »

Whatman™ EasiCollect™+ System for simple, reliable buccal sample collection and storage

EasiCollect™ + System from GE Healthcare’s Life Sciences business addresses the difficulties of buccal cell collection for forensic analysis with an updated design which increases usability and first pass success rates. Providing consistent sample transfer to FTA™ cards, EasiCollect+ simplifies the collection and storage of DNA for genetic analysis in forensics, human identification and SNP genotyping.

Read more »

Median Cost Per Patient for Orphan Drugs is 5.5 Times Higher Than Non-Orphan Drugs

LONDON, BOSTON, TOKYO  – The steady and inexorable growth of the orphan drug market remains one of the prominent themes in the fourth edition of the EvaluatePharma Orphan Drug Report 2017. What has changed in the last 12 months according to the report is the increased scrutiny of the price of these lifesaving products.

Read more »

Halaven® (eribulin) launches in South Africa for the treatment of women with advanced breast cancer

Halaven® (eribulin) is now available in South Africa for the treatment of women with locally advanced or metastatic breast cancer who have received at least two chemotherapeutic regimens for their advanced disease. Prior therapy should have included an anthracycline and a taxane, unless patients were not suitable for these treatments.

Read more »

Congenica raises £8M ($10M) in Series B financing round to drive international expansion of its genome analysis business

CAMBRIDGE, UK - Congenica, a leading provider of clinical genome analysis technology, announced today that it has raised £8m ($10m) in its Series B financing round. Existing investors, Cambridge Innovation Capital plc (CIC) and Amadeus Capital Partners (Amadeus) participated alongside new investor, Parkwalk Advisors (Parkwalk).

Read more »